NewAmsterdam Pharma (NAMS) Receivables - Other (2021 - 2026)

NewAmsterdam Pharma (NAMS) has 5 years of Receivables - Other data on file, last reported at $8.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 455.83% year-over-year to $8.0 million; the trailing twelve-month figure through Mar 2026 stood at $8.0 million (up 455.83% YoY), and the FY2025 full-year result was $6.8 million, up 287.01% from the prior year.
• Receivables - Other climbed to $8.0 million in Q1 2026, from $6.8 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $8.0 million in Q1 2026 to a low of $875000.0 in Q4 2023.
• A 4-year average of $3.4 million and a median of $2.7 million in 2024 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other plunged 63.81% in 2025 and jumped 455.83% in 2026, its largest moves.
• Tracing NAMS's Receivables - Other over 4 years: stood at $875000.0 in 2023, then jumped by 99.77% to $1.7 million in 2024, then jumped by 287.01% to $6.8 million in 2025, then increased by 18.48% to $8.0 million in 2026.
• Business Quant data shows NAMS's Receivables - Other at $8.0 million in Q1 2026, $6.8 million in Q4 2025, and $3.9 million in Q3 2025.